The launch of Nerivio in Germany represents a significant step for Dr. Reddy's into the digital therapeutics space in Europe, a move that could open up new revenue streams and market presence. Given the FDA approval and CE-mark certification, the product has a strong regulatory backing, which could positively influence investor sentiment and potentially lead to a short-term uptick in RDY's stock price.